s6y

Rezolute, Inc.

Ticker
RZLT
CIK
1509261
Industry
Pharmaceutical Preparations
Formerly
AntriaBio, Inc., FITS MY STYLE INC

Financials 71

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-K Annual Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-Q Quarterly Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-K Annual Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-Q Quarterly Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-K Annual Report for period ending Jun 30, 2024

All 71 financials filings

News 189

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 189 news filings

Ownership 251

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 251 ownership filings

Prospectus 88

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  3. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  4. S-3 Registration statement for specified transactions by certain issuers
  5. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  6. S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
  7. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  8. S-3 Registration statement for specified transactions by certain issuers
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. 424B5 Prospectus filed pursuant to Rule 424(b)(5)

All 88 prospectus filings

Proxies 28

  1. DEF 14A Definitive proxy statements
  2. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  3. DEF 14A Definitive proxy statements
  4. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  5. DEF 14A Definitive proxy statements
  6. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  7. DEF 14A Definitive proxy statements
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. DEF 14A Definitive proxy statements
  10. DEF 14A Definitive proxy statements

All 28 proxies filings

Other 141

  1. SCHEDULE 13G
  2. SCHEDULE 13G/A
  3. SCHEDULE 13G
  4. EFFECT Notice of Effectiveness
  5. SCHEDULE 13G
  6. SCHEDULE 13G/A
  7. SCHEDULE 13G
  8. SCHEDULE 13G/A
  9. SCHEDULE 13G
  10. SCHEDULE 13G/A

All 141 other filings